Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of five systematic review(s)/meta-analysis(es). ^[1-5]
• Clinical Cure and Improvement with Oritavancin (ORI): In a systematic review of 301 cases treated with multidose ORI, clinical cure was achieved in 85% (231/272) of patients, and clinical improvement was noted in an additional 8% (22/272) of patients, with most cases involving infections such as osteomyelitis, acute bacterial skin and skin structure infections (ABSSSI), and cellulitis.
• Non-Inferiority in ABSSSI Treatment: Meta-analysis findings demonstrated that ORI was statistically non-inferior to control agents in efficacy outcomes for acute bacterial skin and skin structure infections (ABSSSIs), including investigator-assessed clinical cure and lesion size reduction, positioning it as a viable alternative to standard treatments.
• Adverse Events with Oritavancin: In a systematic review, the most common adverse events for patients treated with oritavancin included infusion-related reactions and hypoglycemia. Oritavancin was generally well-tolerated, showing a favorable safety profile across various infections.
• Comparison to Vancomycin: Oritavancin was associated with significantly fewer adverse events than vancomycin (relative risk (RR) = 0.72; P < 0.01) and showed similar all-cause mortality rates, highlighting a potential advantage in tolerability for treating Gram-positive infections.
• Population Types and Specific Infections Treated: The systematic review identified the most common infections treated with oritavancin as osteomyelitis (148 cases), ABSSSI (35 cases), and cellulitis (14 cases), primarily involving methicillin-resistant staphylococcus aureus (MRSA) (121 cases) and methicillin-susceptible staphylococcus aureus (MSSA) (66 cases), with additional isolates of coagulase-negative staphylococci (CoNS), E. faecalis, and E. faecium.
• Subgroup Findings in ABSSSI: In a meta-analysis of ABSSSI treatment, oritavancin significantly reduced the rate of 30-day emergency room visits in outpatient settings (RR = 0.34; P < 0.00001), indicating potential benefits for managing ABSSSI in outpatient care.